Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes
Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes
复制标题
DOI：
10.1136/jitc-2019-000467
复制
发表时间：
2020-01-01
影响因子：
10.9
通讯作者：
Kitchlu, Abhijat
中科院分区：
文献类型：
--
作者：
Meraz-Munoz, Alejandro;Amir, Eitan;Kitchlu, Abhijat
背景免疫检查点抑制物(ICPI)是一种新型的、有发展前景的抗癌药物。在接受ICPI治疗的患者中，关于急性肾损伤(AKI)的发生率、危险因素和预后的数据有限。方法我们对2010-2017年间在我们中心接受ICPI的患者进行了一项队列研究，通过电子健康记录进行。主要结果是AKI(较基线血清肌酐(Scr)增加50%)。AKI的危险因素用Logistic回归进行评估。采用Kaplan-Meier方法比较AKI患者和非AKI患者的存活率。结果在接受ICPI治疗的309例患者中，51例(16.5%)发展为AKI(肾脏疾病改善全球预后(KDIGO)期：1：53%、2：22%、3：25%)。AKI与其他免疫相关不良事件(IRAE)相关(OR 3.2，95%CI 1.6~6；p
Background Immune checkpoint inhibitors (ICPi) are a novel and promising anti-cancer therapy. There are limited data on the incidence, risk factors and outcomes of acute kidney injury (AKI) in patients receiving ICPi. Methods We conducted a cohort study of patients receiving ICPi at our center between 2010 and 2017 via electronic health record. The primary outcome was AKI (increase of >50% from baseline serum creatinine (sCr)). Risk factors for AKI were assessed using logistic regression. Survival among those with and without AKI was compared using the Kaplan-Meier method. Results Among 309 patients on ICPi, 51 (16.5%) developed AKI (Kidney Disease Improving Global Outcomes (KDIGO) stages 1: 53%, 2: 22%, 3: 25%). AKI was associated with other immune-related adverse events (IRAE) (OR 3.2, 95% CI 1.6 to 6; p